Welcome to the e-CCO Library!

P397: Autologous stem cell transplantation in refractory Crohn's disease: evaluation of a modified mobilisation regimen and analyses of the cost-effectiveness
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. Mahmmod*1, S. Mahmmod2, M. Severs2, H. Koene3, F. van Wijk4, B. Oldenburg2, H. Fidder2

Created: Friday, 22 February 2019, 9:41 AM
P397: Can upskilling pharmacy technicians support a robust and cost-effective Inflammatory Bowel Disease patient review process? A single-centre prospective study.
Year: 2022
Source: ECCO'22
Authors: Rees, F.(1);Packham, A.(1);St Clair Jones, A.(1);Smith, M.(1);
Created: Friday, 11 February 2022, 3:52 PM
P397: Effectiveness of vedolizumab (VDZ) for the induction of remission in inflammatory bowel disease (IBD): Results from the Spanish Eneida Registry
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Chaparro1,2,3,4*, A. Garre1,2,3,4, I. Alfaro4,5, M. Iborra4,6, P. Mesonero7, I. Vera Mendoza8, A. Rodríguez9, J. Miquel-Cusachs10, S. Riestra11, P. Navarro12, L. De Castro Parga13, C. González-Muñoza14, M. Rivero15, M. Mañosa4,16, L. Fernández Salazar17, N. Jiménez18, J. Guardiola19, J. Cabriada20, A. Gutiérrez Casbas4,21, B. Sicilia22, J.L. Pérez Calle23, M. Piqueras24, A. Algaba25, O. Roncero26, A. Bargallo27, E. Sainz28, J. Barrio29, X. Calvet4,30, A. García31, M. Llorente Barrio32, R. Llorente Poyatos33, P. Almela34, R. Madrigal35, A.J. Lucendo Villarín36, R. Pajares37, M. Van Domselaar38, J. Legido Gil39, J.P. Gisbert1,2,3,4

Created: Thursday, 21 February 2019, 9:14 AM
P397: Efficacy and safety of sequential rescue therapy with infliximab and tacrolimus in patients with corticosteroid-refractory ulcerative colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

K. Matsuoka*, E. Saito, T. Fujii, K. Takenaka, F. Iwamoto, M. Kimura, M. Nagahori, K. Ohtsuka, M. Watanabe

Created: Friday, 22 February 2019, 9:49 AM
P397: Response to biologics in IBD patients assessed by Computerized image analysis of Probe Based Confocal Laser Endomicroscopy with molecular labeling
Year: 2021
Source: ECCO'21 Virtual
Authors: Iacucci, M.(1);Grisan, E.(2);Labarile, N.(1);Nardone, O.(1);Smith, S.C.(1);Jeffery, L.(1);Ghosh, S.(1);Buda, A.(3);
Created: Wednesday, 2 June 2021, 4:12 PM
P398 The early appearance of anti-drug antibodies during the induction phase predicts the clinical response of adalimumab and infliximab in IBD
Year: 2020
Source:

ECCO'20 Vienna

Authors:

X. Roblin1, N. williet1, P. veyrard1, G. boschetti2, A.E. berger3, S. nancey2, B. flourie2, S. paul3

Created: Thursday, 30 January 2020, 10:12 AM
P398: An objective measure of response to treatment for patients with Crohn's perianal fistulas on anti-TNF treatment
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sahnan K.*1, Lung P.F.2, Adegbola S.O.1, Burling D.2, Burn J.2, Tozer P.J.1, Gupta A.2, Faiz O.D.1, Phillips R.K.1, Hart A.L.3

Created: Wednesday, 20 February 2019, 10:36 AM
P398: Cannabis induces clinical and endoscopic improvement in moderately active ulcerative colitis (UC)
Year: 2018
Source: ECCO '18 Vienna
Authors:

T. Naftali1,2*, L. Bar Lev Schlieder3, F. Sklerovsky Benjaminov1,2, I. Lish2,4, J. Hirsch4, F.M. Konikoff1,2

Created: Thursday, 21 February 2019, 9:14 AM
P398: Disease clearance: a potential target for management of patients with Ulcerative Colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Andronic, A.M.(1)*;Toader, E.(1);
Created: Friday, 14 July 2023, 11:05 AM
P398: Effect of Intravenous versus Oral Iron Therapy on Physical Fitness and Haemoglobin in Paediatric IBD Patients with Anaemia
Year: 2021
Source: ECCO'21 Virtual
Authors: Bevers, N.(1);van de Vijver , E.(2);Aliu , A.(1);Rezazadeh Ardabili , A.(3);Rosias , P.(1);Busari , J.(4);Stapelbroek , J.(5);Bertrams , I.(6); van der Feen , C.(7);Oudshoorn , A.(8);Teklenburg , S.(9);Escher , J.(10);Vande Velde , S.(11);Winkens , B.(12);Raijmakers , M.(13);Vreugdenhil , A.(14); Pierik , M.(3);van Rheenen , P.(15);
Created: Wednesday, 2 June 2021, 4:12 PM
P398: Leptin controls immune cell composition and activity in acquired generalised lipodystrophy with combined Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. F. Ziegler*1, C. Böttcher2, H. Wu1, R. Glauben1, B. Siegmund1, C. Weidinger1,3

Created: Friday, 22 February 2019, 9:41 AM
P398: Long term efficacy and safety of ABP 501 adalimumab biosimilar in inflammatory bowel diseases: preliminary results from the ADASWITCH study
Year: 2022
Source: ECCO'22
Authors: Cingolani, A.(1);Felice, C.(2);Lombardi, G.(3);Onidi, F.M.(4);Checchin, D.(5);Colucci, R.(6);Grossi, L.(7);Ferronato, A.(8);Rocchi, C.(9);Ascolani, M.(10);Binaghi, L.(4);Dore, M.F.(4);Fanini, L.(11);Bulajic, M.(9);MocciMD FRCP, G.(4);
Created: Friday, 11 February 2022, 3:52 PM
P398: The costs of care for patients with ulcerative colitis: effect of adalimumab on health care resources utilisation in clinical practice from INSPIRADA
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Travis*1, B. Feagan2, L. Peyrin-Biroulet3, R. Panaccione4, S. Danese5, A. Lazar6, A. Robinson7, J. Petersson7, M. Bereswill6, M. Skup7, N. Chen7, S. Wang7, R. Thakkar7, J. Chao7

Created: Friday, 22 February 2019, 9:49 AM
P399 Endoscopic and histologic outcome in tofacitinib treated refractory moderate-to-severe ulcerative colitis: A prospective real-life cohort
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Verstockt1, A. Outtier1, J. Lefrère1, J. Sabino1, S. Vermeire1, G. De Hertogh2, M. Ferrante2

Created: Thursday, 30 January 2020, 10:12 AM
P399: Adverse events associated with azathioprine treatment in Korean pediatric inflammatory bowel disease patients
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kim M.

Created: Wednesday, 20 February 2019, 10:36 AM
P399: C-Reactive Protein Values After Surgery for Inflammatory Bowel Disease: Is It Still A Good Marker For Intra-Abdominal Complication? A Retrospective Cohort Study of 347 procedures.
Year: 2022
Source: ECCO'22
Authors: Gaspard, B.(1);Alexandre, C.(1);thibault, V.(1);Lauren, O.(2);Clotilde, D.(1);Najim, C.(1);yann, P.(1);Lefevre, J.(1);
Created: Friday, 11 February 2022, 3:52 PM
P399: Cost-effectiveness of utilising proactive Infliximab therapeutic drug monitoring for inflammatory bowel disease in routine clinical practice
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Steen*1, M. McCormack2, C. McShane1, M. Healy2, V. Crowley2, U. Kennedy1, O. Hayes1, C. Dunne1, K. Hartery1, S. McKiernan1, F. MacCarthy1, D. Kevans1

Created: Friday, 22 February 2019, 9:41 AM
P399: Detection of iron restricted erythropoiesis in patients with IBD: How can we disentangle effects of inflammation?
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Aksan, A.(1,2,3)*;Mangold, C.(4);Stötzel, J.(1,3);Tessmer, L.(3,5);Schröder, O.(3,5);Stein, J.M.(3,5,6);
Created: Friday, 14 July 2023, 11:05 AM
P399: Higher anti-tumour necrosis factor-alpha drug levels are associated with improved radiological outcomes in patients with perianal fistulising Crohn’s disease: A retrospective multi-centre study
Year: 2021
Source: ECCO'21 Virtual
Authors: De Gregorio, M.(1,2);Lee, T.(1);Krishnaprasad, K.(1,3);Amos, G.(4,5);An, Y.K.(4,6);Bastian-Jordan, M.(4,5);Begun, J.(6,7);Borok, N.(8,9);Brown, D.J.M.(10);Cheung, W.(11);Connor, S.(12,13,14);Gerstenmaier, J.(11);Gilbert, L.E.(15);Gilmore, R.(16);Gu, B.(12,14,17);Kutaiba, N.(18,19);Lee, A.(20,21);Mahy, G.(22);Srinivasan, A.(16,23,24);Thin, L.(25,26);Thompson, A.(1,2);Welman, C.J.(27);Yong, E.X.(28);De Cruz, P.(2,16);van Langenberg, D.(23,24);Sparrow co-lead senior author, M.(15,24);Ding, N.S.(1,2);
Created: Wednesday, 2 June 2021, 4:12 PM
P399: Testing patients initiating anti-TNFα agents for mycobacterial infection using interferon-gamma release assays (IGRA): The combined experience of a large dermatology and Inflammatory Bowel Disease service
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Rajagopal*1, K. Greveson2, S. McBride3, A. Waite3, M. Lipman4, C. Murray2

Created: Friday, 22 February 2019, 9:49 AM